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Abstract
Background: Atrial fibrillation is a common cause of stroke and other morbidity. Adequate treatment with
anticoagulants reduces the risk of stroke by 60 %. Early detection and treatment of atrial fibrillation could prevent
strokes. Atrial fibrillation is often asymptomatic and/or paroxysmal.
Case-finding with pulse palpation is an effective screening method, but new methods for detecting atrial fibrillation
have been developed. To detect paroxysmal atrial fibrillation ambulatory rhythm recording is needed.
This study aims to determine the yield of case-finding for atrial fibrillation in primary care patients. In addition, it will
determine the diagnostic accuracy of three different case-finding methods.
Methods/Design: In a multicenter cluster randomised controlled trial, we compare an enhanced protocol for
case-finding of atrial fibrillation with usual care. We recruit 96 practices. We include primary care patients aged 65 years
or older not diagnosed with atrial fibrillation. Within each practice, a cluster of 200 patients is randomly selected and
marked. Practices are evenly randomised to intervention or control group. The allocation is not blinded.
When a marked patient visits an intervention practice, the case-finding protocol starts, consisting of: pulse palpation,
sphygmomanometer with automated atrial fibrillation detection and handheld single-lead electrocardiogram (ECG). All
patients with at least 1 positive test and a random sample of patients with negative tests receive a 12-lead ECG.
Patients without atrial fibrillation on the 12-lead ECG, undergo additional continuous Holter and use the handheld
single-lead ECG at home for 2 weeks.
Control practices provide care as usual.
The study runs for 1 year in each cluster. The primary outcomes are the difference in detection rate of new AF
between intervention and control practices and the accuracy of three index tests to diagnose AF. We are currently
recruiting practices.
The ‘Detecting and Diagnosing Atrial Fibrillation’ (D2AF) study will determine the yield of an intensive case-finding
strategy and the diagnostic accuracy of three index tests to diagnose atrial fibrillation in a primary care setting.
Trial registration: Netherlands Trial Register: NTR4914, registered on the 25 of November 2014.
Keywords: Atrial fibrillation, Case-finding, ECG, Pulse palpation, Elderly population, Primary care setting, General
practitioner, Stroke, Cardiovascular risk
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Background
Atrial fibrillation (AF) is a common cardiac arrhythmia,
associated with substantial health risks. AF increases
mortality, reduces the quality of life and increases the
risk of heart failure. Moreover, AF is an important risk
factor for stroke. Prevalence of AF increases with age,
from 1 % in the general population up to 7–8 % in
people over 65 years old [1, 2]. With increasing age, pa-
tients also have a higher risk of stroke [3]. Up to 30 % of is-
chemic strokes are AF-related [4–6]. Treatment with oral
anticoagulants reduces the risk of stroke by 60 % [7, 8].
However, in nearly a quarter of patients with stroke AF is
detected after this event [9]. If we can detect AF before a
stroke occurs and start anticoagulant therapy when appro-
priate, we may be able to prevent more than half of AF-
related strokes [4, 6, 9–11].
Although AF can be a symptomatic condition with pa-
tients experiencing palpitations, exercise intolerance or
fatigue, AF often is asymptomatic [12] and remains un-
detected. Furthermore, patients can have recurrent inter-
mittent episodes of AF, paroxysmal AF (pAF). As with
persistent AF, the risk of stroke is substantially increased
in patients with pAF [13, 14]. Therefore, detecting pAF
is as important as detecting persistent AF, but more
challenging.
To establish the diagnosis of AF, an electrocardiogram
(ECG) recording – either on a regular 12-lead ECG or a
30-second rhythm strip – has to be made showing ir-
regular RR intervals without distinct P waves. When
used as screening tools, ECG and ambulatory rhythm re-
cording are costly and time-consuming. Case-finding in
general practice using pulse palpation, improved the de-
tection of AF compared with care as usual (incidence of
AF 1.63 % versus 1.04 %, difference 0.59 %, 95 % CI
0.20 % to 0.98 %) [15]. Opportunistic screening in pa-
tients aged 65 years and over was as effective as system-
atic screening but at lower costs [15].
Recently, new methods for detecting AF have been devel-
oped [16]. One development is the equipment of automatic
sphygmomanometers with an algorithm for irregular beat
detection (eBPM-AF). The National Institute for Health
and Clinical Excellence (NICE) guideline advocates
the use of one of these devices, i.e. the Microlife®
WatchBP Home A device [17]. Other methods use a
single-lead ECG. The MyDiagnostick (Applied Biomedical
Systems® (ABS), Maastricht, The Netherlands) is an ex-
ample of a handheld ECG device, which records a single-
lead ECG (left-right arm) [18].
To detect cases of pAF, ambulatory rhythm recording
is needed [19]. Traditionally, either 24-hour Holter or
event recording is used. In post-stroke patients, a 30-day
period of automatically triggered event recording in-
creased the detection rate of pAF 5-fold compared with
a 24-hour Holter (detection rate of 16.1 % versus 3.2 %)
[20]. In primary care patients with palpitations, monitor-
ing for 14 days diagnosed about 80 % of relevant ar-
rhythmias [19].
New developments have enabled the use of continuous
ECG registrations for longer periods (continuous Holter)
and make loop recording unnecessary. In general, ambu-
latory rhythm recording is used in symptomatic patients
or as part of follow-up after stroke. There is insufficient
evidence about the effectiveness of ambulatory rhythm
registration for the detection of AF in asymptomatic pa-
tients (in general practice). This is a major evidence gap
and further research is recommended [21, 22].
The ‘Detecting and Diagnosing Atrial Fibrillation’
(D2AF) study investigates whether enhanced opportunis-
tic case-finding – using pulse palpation, single-lead
handheld ECG and eBPM-AF – increases detection of
AF in general practice patients of 65 years and over.
Additionally, the study determines the most effective
method of case-finding by comparing the diagnostic
yield of pulse palpitation, handheld ECG and eBPM-AF
alone and in combination.
Methods
Design
We perform a multicenter cluster randomised controlled
trial (RCT) comparing enhanced case-finding of AF with
usual care. In each practice, the study runs for 1 year. In
the intervention arm, we run a diagnostic study compar-
ing 3 different methods for case-finding of AF with a
composite reference standard consisting of a 12-lead
ECG and a 2 week Holter. This way, we determine the
yield of each method individually and combined to de-
tect unknown AF. Figure 1 shows a flowchart of the
study design.
Ethics
The D2AF study proposal was approved by the medical eth-
ical board of the Academic Medical Center in Amsterdam
(dated 14 November 2014, number NL48215.018.14). The
D2AF study is registered at The Netherlands Trial Register
(NTR number NTR4914).
Participants: practices and patients
General practices are recruited across The Netherlands.
We regard two or more general practices sharing facil-
ities as one practice. Within each practice, we form one
cluster by selecting a random fixed sample of two hun-
dred patients out of the eligible patients.
The inclusion criterion for selection of the cohort is
an age of 65 years and over; the exclusion criterion is
previously documented AF. Additional criteria are ap-
plied only to patients in the intervention group for
whom case-finding would be inappropriate (see inter-
vention practices). After selection of the study cohort,
Uittenbogaart et al. Trials  (2015) 16:478 Page 2 of 8
we extract the medical files to determine the baseline
characteristics (e.g. age, sex and medical history includ-
ing heart disease, hypertension, previous stroke/transient
ischaemic attack (TIA), diabetes).
All data are entered into our secured trial management
system. This system also gathers all other data during
the study. Investigators enter data directly into the sys-
tem using electronic case record forms (eCRF).
Cluster randomisation
Clusters are evenly allocated to either the intervention
or the control group using stratified randomisation. To
stratify clusters, we determine the prevalence of AF in
all patients aged 65 years and over in participating clus-
ters using International Classification of Primary Care
(ICPC)-codes in the medical files. Subsequently, we
stratify clusters in high-prevalence and low-prevalence
clusters. As a cut-off we use the average prevalence of
AF in the associated general practices of the 2 univer-
sities involved in this study: 8.05 %. We use compu-
terised randomisation in permuted blocks of random
sizes. After randomisation, the investigator informs the
participating practices of the allocation.
Intervention practices
In each practice, the selected 200 patients are marked in
the medical records of the practice before the start of
the study. When a marked patient makes an appoint-
ment for a consultation at the practice we ask him or
her to participate. The sub-investigator (practice nurse,
practice assistant or general practitioner) does not carry
out the intervention in patients not suited for case-
finding based on the following criteria:
– having a pacemaker or implantable cardioverter-
defibrillator (ICD)
– legal incompetence or inability to give informed
consent
– suffering from a terminal illness (as defined by the
general practitioner)
– inability to come to the practice to participate in the
diagnostic process; for instance, a patient who is
chronically bedridden. Patients who cannot visit the
practice due to a temporary situation (such as the
flu) are not excluded
The reason is noted in the trial management system.
All patients who undergo the case-finding protocol in
Fig. 1 Study design of ‘Detecting and Diagnosing Atrial Fibrillation’ D2AF. GP, general practitioner; hand-ECG, handheld ECG device; eBPM-AF,
automatic sphygmomanometer with an algorithm for irregular beat detection; ECG, electrocardiogram
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the intervention group will be asked written informed
consent. We do not ask informed consent in the control
group since we merely analyse these patients on a group
level. They receive care as usual and we do not want to
trigger additional awareness of AF.
Diagnostic tests
The sub-investigator collects the baseline information
on the patient history, weight, length and current symp-
toms indicative of AF. Subsequently, the sub-investigator
performs the following three index tests in all study
patients:
Pulse palpation: manual palpation of the radial artery
in the wrist with the fingertips for a minimum of 15 sec-
onds. The frequency is registered. The heart rhythm is
classified as ‘regular’, ‘one to three skipped or extra beats’
or ‘irregular’. Both ‘one to three skipped or extra beats’
and ‘irregular’ are regarded as a positive result. The fill-
ing pressure is classified as ‘equal’ or ‘unequal’.
eBPM-AF: the WatchBP Home A (Microlife®, Widnau,
Switzerland) is an electronic sphygmomanometer with
an algorithm for irregular beat detection. The algorithm
calculates the irregularity index based on the interval
time between heartbeats and indicates an irregular pulse
if the threshold is exceeded. A cuff is applied around the
patient’s left or right upper arm. The cuff inflates and
deflates automatically after pressing the ‘ON’ button.
The display shows the average of three blood pressure
measurements. If an irregular pulse is detected in at
least two out of three measurements, an icon on the dis-
play saying ‘Afib’ starts blinking [17]. If the device is not
able to correctly analyse the rhythm this is noted in the
eCRF.
Handheld ECG at the practice: the MyDiagnostick
(ABS, Maastricht, The Netherlands) is a 24-cm long bar
with metallic electrodes at both ends. It records a single-
lead ECG (left-right arm). The device switches on auto-
matically when holding it with both hands. An automatic
algorithm calculates a rhythm-score, periodicity-score and
variability-score based on computed intervals between
two R waves. If the threshold is exceeded, a red light indi-
cates possible AF. The outcome of the handheld ECG is
noted in the eCRF. If the device cannot make a recording
this is registered. Recordings are stored locally and are
uploaded as a PDF in the local PC application [23].
The order in which the index tests are performed is set.
Pulse palpation is performed and recorded first. Then, by
an alternating pre-set order in the eCRF, both eBPM-AF
and handheld ECG are performed and recorded.
All patients scoring positive on at least 1 of the 3 index
tests will receive a 12-lead ECG in the same session as the
index tests. To calculate sensitivity and specificity of the
screening procedure, a random sample of 10 % of patients
who score negative on all 3 index tests also receive a 12-
lead ECG. An overview of these procedures can also be
seen in Fig. 1. The sub-investigator is blinded to the ECG
results while performing the index tests.
12-lead ECG: the 12-lead ECG device (Fysiologic®,
Amsterdam, The Netherlands) is paperless and does not
display the ECG. The ECG is transferred digitally and
assessed by an experienced assessor, supervised by a car-
diologist. In case the ECG shows any serious clinically
relevant abnormality, the general practitioner (GP) is no-
tified immediately. A second cardiologist re-assesses all
AF-diagnosed ECGs and a random sample of negative
ECGs. Both cardiologists are provided with basic data
such as age and gender but are blinded to all previous
measurements. Any disagreement on diagnosis is solved
by a third cardiologist. AF is defined as the absence of dis-
tinct P waves and a completely irregular RR interval [24].
If a patient is diagnosed with AF, the study protocol is
finished. Results of the ECG are reported back to the
GP, who provides care at his discretion.
In patients in whom no AF is diagnosed on a 12-lead
ECG, 2 additional tests are performed to detect pAF:
Handheld ECG at home: the same device
(MyDiagnostick, ABS, Maastricht, The Netherlands) as
mentioned above is used, but the indication light is set
off. Thus, the patient is blinded for the results of the
test (light will not blink). The patient is instructed to
use the handheld ECG three times a day at set times.
After 2 weeks of recording, data are uploaded as PDF
in the local PC-application. The MyDiagnostick can
store up to 140 ECG strips.
Two-week Holter: the same device (Fysiologic®,
Amsterdam, The Netherlands) as for the 12-lead ECG
is used. The wiring has four different patches instead
of ten. With these 4 patches, leads V1 and V5 are
obtained. The patient receives a small disposable
shoulder bag to wear the device and several sets of
patches with instructions so they can change them.
After 2 weeks of continuous recording, data are
transferred and assessed by an experienced assessor,
supervised by a cardiologist. The number and duration
of AF episodes are registered. In case the ECG shows
any serious clinically relevant abnormalities, the GP is
notified immediately. A second cardiologist, blinded to
previous assessments re-assesses all AF-diagnosed
Holters. Furthermore, a random sample of negative
Holters is re-assessed. We define AF as any arrhythmia
that has the characteristics of AF (see above) and lasts
at least 30 seconds [24].
Diagnoses ‘atrial fibrillation’
To diagnose AF, we use a composite reference standard
consisting of the results of the 12-lead ECG and the
2-week Holter as defined previously.
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Besides cases found with our case-finding protocol,
we will also perform computer searches of the med-
ical records to identify all new cases of AF. We ask
the sub-investigator to report how the diagnosis was
established in new cases of AF not detected with the
intervention.
Quality of life
Little is known of the quality of life of asymptomatic AF
patients. To investigate this, we use the EuroQol 5D
(EQ-5D) questionnaire to measure quality of life. EQ-5D
is a generic tool that assesses five dimensions of health-
related quality of life by use of a questionnaire and a vis-
ual analogue scale [25]. We opt for 1000 patients in the
intervention practices to participate: all patients with
newly diagnosed AF saturated with a random sample of
patients not diagnosed with AF. The reason for the visit
may affect quality of life at the time of the visit. There-
fore, we delay the timing of the questionnaire until the
end of the study year.
Control practices
In each practice, the selected 200 patients are marked
in the medical records of the practice before the start
of the study, but the marking is blinded to the sub-
investigators. Neither the sub-investigators nor the
patients are aware of participation in the study. The
control practices perform ‘usual care’ at the discretion
of the GP. Currently, the guideline on AF of the
Dutch College of General Practitioners does not rec-
ommend screening for AF. Pulse palpation is not car-
ried out systematically.
At the end of the study year, we perform computer
searches of the medical records to identify all new cases
of AF in the control practices. We evaluate the route
that led to the diagnosis of AF. To that end, we will
study the patients’ files to determine the path by which
the diagnosis AF is made.
End of the study




1. The yield of a case-finding strategy for AF (including
paroxysmal and asymptomatic AF) compared with
care as usual.
2. The diagnostic accuracy (sensitivity and specificity)
of each of the three index tests (pulse palpation,
eBPM-AF and handheld ECG) to diagnose AF and
the accuracy of various combinations of case-finding
strategies with the results of the 12-lead ECG and 2-
week Holter as reference standard.
Secondary outcome measures
1. The incidence and prevalence of AF (including
paroxysmal and asymptomatic) in patients aged
65 years and over in Dutch general practice.
2. The diagnostic accuracy (sensitivity and specificity)
of the handheld ECG at home to detect pAF with
the 2-weeks Holter as the reference standard.
3. The quality of life of patients with newly detected
asymptomatic AF compared with healthy controls as
measured with the EQ-5D.
Sample size calculation
The primary outcome is the difference in the detection
rate of new AF in 1 year between intervention and con-
trol practices. We estimate that the yearly incidence of
new AF in the Netherlands in patients aged 65 and over
is 1.3 % and assume that this is the detection rate in
control practices [26]. In previous research among a
similar group of patients the odds ratio (OR) of newly
identified AF by opportunistic screening compared with
no screening in the control group was 1.61 (95 % CI
1.14–2.29) [15]. In that study, ECG was offered if the
pulse of the patient was irregular. Since we will provide
a more extensive diagnostic programme of various diag-
nostic methods, it is likely that we will find a higher de-
tection rate of (paroxysmal and asymptomatic) AF. We
assume that an OR of 1.8 is reasonable. The detection
rate in the intervention group is estimated at 2.32 %
[27]. To detect an absolute difference of 1.02 % in the
detection rate of new cases of AF between the interven-
tion and control arm of the study with 80 % power at a
significance level of 5 %, we will need 2701 patients in
each group [28]. Outcomes for individuals within clus-
ters may be correlated as we will randomise practices
(i.e. clusters). To take into account the effect of cluster
randomisation we calculate a design effect of 2.99 based
on fixed cluster sizes of 200 patients and an intracluster
correlation coefficient (ICC) of 0.01 [29, 30]. In a study
comparable to ours, an ICC of 0.0027 between practices
was found at the end of the study [15]. Increasing the
sample size by a design effect of 2.99 the number of re-
quired inclusions becomes 8076 patients per group.
Additionally, we take into account a loss to follow-up of
15 %. After correcting for loss to follow-up we get a total
of 9501 patients. We decided on 48 even cluster sizes of
200 patients which makes a total of 9600 patients. Our
sample size and study design are comparable to the
study by Hobbs et al. [22].
Statistical analysis
We analyse data on an intention-to-screen basis. We
evaluate the outcomes of the intervention on a patient
level.
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Primary study outcomes
1. The difference in yield of new AF in 1 year between
intervention and control practices is estimated by
calculating the difference in detection rate of new
AF (new cases of AF after 1 year within the clusters/
all patients in the clusters) between intervention and
control practices. We use logistic mixed-effects
models with practice as random factor for statistical
analysis, since this accounts for the correlation
between patients within the same practice. In case
the outcome (AF yes/no) is missing for a patient, the
patient is excluded from the analysis (list-wise
deletion). We use multiple imputation to obtain
complete datasets and to see whether the original
analysis is influenced by these missing data: i.e. to
see whether the difference in detection rates
between intervention and control groups is similar
for both the original analysis (list-wise deletion) and
the multiple imputation analysis.
2. Diagnostic test characteristics of the different index
tests to diagnose AF are compared with the results
of the 12-lead ECG and 2-weeks Holter (composite
reference standard). Sensitivity and specificity of
each technique are calculated (including the
corresponding 95 % confidence intervals). Because
not all patients receive the reference standard,
diagnostic parameters are estimated by converting
studied numbers (i.e. results of test and reference
standard) to the source population by multiplying
them with the sample factor. For this, we use
inversed probability weighting [31]. In the intervention
group, we expect an incidence of AF of 2–3 %. This
would result in sufficient numbers in all cells of the
imaginary diagnostic 2x2 tables. We compare the
diagnostic characteristics of the index tests to each
other. We evaluate each method separately and in
different combinations.
Secondary study outcomes
1. We use descriptive statistics in both intervention
and control practices to provide current AF
prevalence and incidence figures in Dutch general
practice.
2. The diagnostic test characteristics of the handheld
ECG device for home monitoring using the 2-week
Holter as reference standard are reported in a 2x2 table.
Sensitivity and specificity (including the corresponding
95 % confidence intervals) are calculated.
3. We use descriptive statistics to describe the
outcomes of the quality of life of patients with
asymptomatic AF and healthy controls.
Categorical data are presented by number of patients (%)
and numerical data by mean (SD) or median (interquartile
range, IQR), where appropriate. IBM SPSS (SPSS Inc.,
Chicago, IL, USA) for Windows and SAS (SAS Institute,
Cary, NC, USA) will be used to analyse the data.
Discussion
The ‘Detecting and Diagnosing Atrial Fibrillation’
(D2AF) study is the first case-finding study to detect AF
in general practice not only using pulse palpation but
also new methods like a single-lead handheld ECG – to
be used at the office and at the patient’s home – and an
electronic sphygmomanometer with the ability to detect
AF while measuring the blood pressure.
In a systematic review, Lowres et al. showed that
screening for AF at one moment can identify previously
undiagnosed AF [32]. The incidence of previously un-
diagnosed AF in patients of 65 years and over was 1.4 %
(CI 1.2–1.6 %). However, when using pulse palpation or
12-lead ECG at only one moment, one risks missing
pAF. A systematic screening programme in a 75-year-
old Swedish population showed that 2 weeks of add-
itional intermittent ECG recording using a single-lead
ECG twice daily (after a negative 12-lead ECG) revealed
newly found pAF in 7.4 % of screened patients [33]. The
D2AF study uses new diagnostic methods and intermit-
tent ECG recording to detect persistent and paroxysmal
AF. By comparing the new methods (eBPM-AF and
handheld ECG) and pulse palpation, we will be able to
determine the diagnostic gain of each method separately
and of combined strategies. Furthermore, we will deter-
mine the gain of using the handheld ECG at home for a
prolonged period.
We use cluster randomisation to prevent control pa-
tients from being contaminated with awareness of AF
detection or with the availability of additional equip-
ment. We use a fixed sample size of 200 patients, as a
compromise between statistical power and an acceptable
workload for the general practices.
We focus on patients aged 65 years and over, because
of the increasing prevalence of AF with age from about
1 % in the whole population to about 5 % in people aged
over 65 [34]. Moreover, detecting AF in this age group
has treatment consequences in most patients. According
to the CHA2DS2VASc score all women and most men of
65 years and over with AF are eligible for anticoagula-
tion. By recruiting in different regions, we include prac-
tices with diversity in organisation and patients
characteristics, such as ethnicity.
Besides the actual prevalence in the patient group, the
efforts the doctors made to detect AF in the past deter-
mines the registered prevalence of AF in each cluster.
Therefore, we expect the registered prevalence of AF in
each practice to correlate negatively with the chance of
detecting new AF. We will use prevalence of AF in pa-
tients aged 65 years and older as our stratification
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variable to equalise the chance of finding new AF in the
intervention and control practices.
We use a case-finding protocol, which means that only
patients making an appointment for a consultation are
asked to participate. We preferred this method to system-
atic screening, where all patients are asked to participate.
One of the reasons is that Hobbs et al. showed case-
finding to be as effective as systematic screening [15].
In the intervention arm, we run a diagnostic study to
determine the test characteristics of different case-
finding methods for AF. Ideally, one should perform the
reference standard in all patients. We considered this as
too costly, time-consuming and interruptive for both pa-
tients and practices. Therefore, we decided to perform
the composite reference test only in patients with a posi-
tive case-finding test and a small random group of pa-
tients with negative tests.
AF is an important risk factor for stroke, and early de-
tection is desirable to enable prevention of serious com-
plications. The D2AF study will provide valuable
evidence on the efficacy of case-finding and on the best
methods for detecting AF.
Trial status
The trial has started September 2015 in the first prac-
tices. We are currently completing the recruitment of
practices.
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